Developing therapeutic antibodies for Alzheimer's disease

点击翻译按钮获取中文摘要

PROJECT SUMMARY/ABSTRACT Millions of Americans suffer from Alzheimer’s disease and there are currently no therapies available to prevent or slow the progression of the disease. The unmet medical needs of individuals with Alzheimer’s disease result in hundreds of billions of dollars of costs in paid and unpaid caregiving in the United States every year. VersaPeutics is a small business developing novel therapeutics for Alzheimer’s disease. In this Phase I SBIR project we will perform preclinical studies to determine the feasibility of antibody-based therapeutics that are designed to treat Alzheimer’s disease using a unique mechanism of action, by examining pharmacokinetics, efficacy, toxicity and toxicokinetic. At the conclusion of these studies, we will have met several important milestones that will support further preclinical development of our novel therapeutics for Alzheimer’s disease.